Shopping Cart 0
Cart Subtotal
USD 0

Mayne Pharma Group Ltd (MYX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Mayne Pharma Group Ltd (Mayne Pharma), formerly HalcyGen Pharmaceuticals Ltd, a subsidiary of Mayne Pharma Group Ltd, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company's products comprise erymax capsules, kapanol capsules, doryx capsules, magnoplasm, astrix capsules and tablets, and lozanoc and itragerm capsules. It offers services such as analytical development, product development, contract manufacturing, logistics, and formulation development, others. Mayne Pharma offers its products in the dosage forms of tablets, capsules, powders, liquids, and creams. The company operates manufacturing facilities in Australia and the US. Mayne Pharma is headquartered in Adelaide, South Australia, Australia.

Mayne Pharma Group Ltd (MYX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Mayne Pharma Acquires Efudex from Spear Pharma 14

Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 15

Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 16

Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 18

Mayne Pharma Acquires Brands And Related Assets For Forest Labs For USD 12 Million 19

Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 20

Venture Financing 21

HedgePath Pharma Raises USD0.6 Million in Financing 21

Partnerships 22

Mayne Pharma Enters into Distribution Agreement with IDT Australia 22

Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 23

Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 25

Licensing Agreements 27

HedgePath Pharma Enters into Option Agreement with University of Connecticut 27

Mayne Pharma Enters into Licensing Agreement with Nestle Skin Health 28

HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 29

HedgePath Pharma Amends Licensing Agreement With Mayne Pharma 30

Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 32

Equity Offering 33

HedgePath Pharma Raises USD1.6 Million in Second Tranche of Private Placement of Preferred Shares 33

HedgePath Pharma Raises USD2.4 Million in First Tranche of Private Placement of Preferred Shares 34

Mayne Pharma Raises USD257 Million in Rights Offering of Shares 35

Mayne Pharma to Raise USD212 Million in Private Placement of Shares 37

HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 39

HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 40

HedgePath Pharma Completes Private Placement of Shares for USD1.5 Million 41

Mayne Pharma Completes Private Placement Of Shares For USD 16 Million 42

Mayne Pharma Group Completes Private Placement Of Shares For USD 5 Million 43

Mayne Pharma Group Completes Private Placement Of Shares For USD 0.14 Million 44

Mayne Pharma Group Completes Private Placement Of Shares For USD 19 Million 45

Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For USD 4 Million 47

Acquisition 48

Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 48

Mayne Pharma Completes Acquisition Of Metrics For Up To USD 120 Million 49

Mayne Pharma Group Ltd-Key Competitors 51

Mayne Pharma Group Ltd-Key Employees 52

Mayne Pharma Group Ltd-Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Recent Developments 55

Strategy And Business Planning 55

Apr 18, 2018: Mayne Pharma Opens New Solid Oral-dose Manufacturing Facility In US 55

Financial Announcements 56

Aug 24, 2018: Mayne Pharma reports FY 18 result s underpinned by a significantly stronger second half 56

Feb 23, 2018: Mayne Pharma Reports 2018 Half Year Performance 59

Aug 25, 2017: Mayne Pharma Reports FY17 Results 62

Feb 24, 2017: Mayne Pharma: 2017 Half Year Release 65

Corporate Communications 68

Jun 28, 2018: Mayne Pharma Names Patrick Blake As New Director 68

May 30, 2018: Mayne Pharma Announces New Board Director 69

Mar 09, 2017: Mayne Pharma appoints new Group CFO and Company Secretary 70

Jan 16, 2017: Mayne Pharma Announces Leadership Changes 71

Other Significant Developments 73

Aug 08, 2017: Mayne Pharma Market Update 73

Appendix 75

Methodology 75

About GlobalData 75

Contact Us 75

Disclaimer 75


List Of Figure

List of Figures

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mayne Pharma Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Mayne Pharma Acquires Efudex from Spear Pharma 14

Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 15

Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 16

Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 18

Mayne Pharma Acquires Brands And Related Assets For Forest Labs For USD 12 Million 19

Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 20

HedgePath Pharma Raises USD0.6 Million in Financing 21

Mayne Pharma Enters into Distribution Agreement with IDT Australia 22

Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 23

Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 25

HedgePath Pharma Enters into Option Agreement with University of Connecticut 27

Mayne Pharma Enters into Licensing Agreement with Nestle Skin Health 28

HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 29

HedgePath Pharma Amends Licensing Agreement With Mayne Pharma 30

Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 32

HedgePath Pharma Raises USD1.6 Million in Second Tranche of Private Placement of Preferred Shares 33

HedgePath Pharma Raises USD2.4 Million in First Tranche of Private Placement of Preferred Shares 34

Mayne Pharma Raises USD257 Million in Rights Offering of Shares 35

Mayne Pharma to Raise USD212 Million in Private Placement of Shares 37

HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 39

HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 40

HedgePath Pharma Completes Private Placement of Shares for USD1.5 Million 41

Mayne Pharma Completes Private Placement Of Shares For USD 16 Million 42

Mayne Pharma Group Completes Private Placement Of Shares For USD 5 Million 43

Mayne Pharma Group Completes Private Placement Of Shares For USD 0.14 Million 44

Mayne Pharma Group Completes Private Placement Of Shares For USD 19 Million 45

Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For USD 4 Million 47

Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 48

Mayne Pharma Completes Acquisition Of Metrics For Up To USD 120 Million 49

Mayne Pharma Group Ltd, Key Competitors 51

Mayne Pharma Group Ltd, Key Employees 52

Mayne Pharma Group Ltd, Other Locations 53

Mayne Pharma Group Ltd, Subsidiaries 53

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Mayne Pharma Group Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.